About recursion pharmaceuticals inc - RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
RXRX At a Glance
Recursion Pharmaceuticals, Inc.
41 South Rio Grande Street
Salt Lake City, Utah 84101
| Phone | 1-385-269-0203 | Revenue | 74.68M | |
| Industry | Biotechnology | Net Income | -644,759,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 26.924% | |
| Fiscal Year-end | 12 / 2026 | Employees | 600 | |
| View SEC Filings |
RXRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 24.505 |
| Price to Book Ratio | 1.91 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.055 |
| Enterprise Value to Sales | 15.534 |
| Total Debt to Enterprise Value | 0.067 |
RXRX Efficiency
| Revenue/Employee | 124,468.333 |
| Income Per Employee | -1,074,598.333 |
| Receivables Turnover | 3.03 |
| Total Asset Turnover | 0.05 |
RXRX Liquidity
| Current Ratio | 5.503 |
| Quick Ratio | 5.503 |
| Cash Ratio | 5.063 |
RXRX Profitability
| Gross Margin | -61.961 |
| Operating Margin | -867.867 |
| Pretax Margin | -863.533 |
| Net Margin | -863.351 |
| Return on Assets | -43.317 |
| Return on Equity | -59.544 |
| Return on Total Capital | -53.337 |
| Return on Invested Capital | -55.869 |
RXRX Capital Structure
| Total Debt to Total Equity | 6.894 |
| Total Debt to Total Capital | 6.45 |
| Total Debt to Total Assets | 5.101 |
| Long-Term Debt to Equity | 4.971 |
| Long-Term Debt to Total Capital | 4.65 |